nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

18.09.2024 | Original Article

Development of STING probes and visualization of STING in multiple tumor types

verfasst von: Huanhuan Liu, Jia Liu, Yingxi Chen, Hongzhang Yang, Jianyang Fang, Xinying Zeng, Jingru Zhang, Shilan Peng, Yuanyuan Liang, Rongqiang Zhuang, Gang Liu, Xianzhong Zhang, Zhide Guo

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2025

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The stimulator of interferon genes (STING) is a critical component of the innate immune system and plays a pivotal role in tumor immunotherapy. Developing non-invasive in vivo diagnostic methods for visualizing STING is highly valuable for STING-related immunotherapy. This work aimed to build a noninvasive imaging platform that can dynamically and quantitatively monitor tumor STING expression.

Methods

We investigated the in vivo positron emission tomography (PET) imaging of STING-expressing tumors (B16F10, MC38, and Panc02) with STING-targeted radioprobe ([¹⁸F]F-CRI₁). The expression of STING in tumors was quantified, and correlation analysis was performed between these results and the outcomes of PET imaging. Furthermore, we optimized the structure of [¹⁸F]F-CRI_n with polyethylene glycol (PEG) to improve the pharmacokinetic characteristics in vivo. A comprehensive comparison of the imaging and biodistribution results obtained with the optimized probes was conducted in the B16F10 tumors.

Results

The PET imaging results showed that the uptake of [¹⁸F]F-CRI₁ in tumors was positively correlated with the expression of STING in tumors (r = 0.9184, P < 0.001 at 0.5 h). The lipophilicity of the optimized probes was significantly reduced. As a result of employing optimized probes, B16F10 tumor-bearing mice exhibited significantly improved tumor visualization in PET imaging, along with a marked reduction in retention within non-target areas such as the gallbladder and intestines. Biodistribution experiments further validated the efficacy of probe optimization in reducing uptake in non-target areas.

Conclusion

In summary, this work demonstrated a promising pathway for the development of STING-targeted radioprobes, advancing in vivo PET imaging capabilities.

Graphical Abstract

Nur mit Berechtigung zugänglich

Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455:674–8. https://doi.org/10.1038/nature07317.CrossRefPubMedPubMedCentral

Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339:786–91. https://doi.org/10.1126/science.1232458.CrossRefPubMed

Wu J, Sun L, Chen X, Du F, Shi H, Chen C, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science. 2013;339:826–30. https://doi.org/10.1126/science.1229963.CrossRefPubMed

Shae D, Becker KW, Christov P, Yun DS, Lytton-Jean AKR, Sevimli S, et al. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat Nanotechnol. 2019;14:269–78. https://doi.org/10.1038/s41565-018-0342-5.CrossRefPubMedPubMedCentral

Dane EL, Belessiotis-Richards A, Backlund C, Wang J, Hidaka K, Milling LE, et al. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity. Nat Mater. 2022;21:710–20. https://doi.org/10.1038/s41563-022-01251-z.CrossRefPubMedPubMedCentral

Motedayen Aval L, Pease JE, Sharma R, Pinato DJ. Challenges and opportunities in the Clinical Development of STING agonists for Cancer Immunotherapy. J Clin Med. 2020;9:3323. https://doi.org/10.3390/jcm9103323.CrossRefPubMedPubMedCentral

Le Naour J, Zitvogel L, Galluzzi L, Vacchelli E, Kroemer G. Trial watch: STING agonists in cancer therapy. Oncoimmunology. 2020;9:1777624. https://doi.org/10.1080/2162402x.2020.1777624.CrossRefPubMedPubMedCentral

Wang Y, Luo J, Alu A, Han X, Wei Y, Wei X. cGAS-STING pathway in cancer biotherapy. Mol Cancer. 2020;19:136. https://doi.org/10.1186/s12943-020-01247-w.CrossRefPubMedPubMedCentral

An X, Zhu Y, Zheng T, Wang G, Zhang M, Li J, et al. An analysis of the Expression and Association with Immune Cell Infiltration of the cGAS/STING pathway in Pan-cancer. Mol Ther Nucleic Acids. 2019;14:80–9. https://doi.org/10.1016/j.omtn.2018.11.003.CrossRefPubMed

10.

Song S, Peng P, Tang Z, Zhao J, Wu W, Li H, et al. Decreased expression of STING predicts poor prognosis in patients with gastric cancer. Sci Rep. 2017;7:39858. https://doi.org/10.1038/srep39858.CrossRefPubMedPubMedCentral

11.

Yuan C, Wang X, Liu Z, Li C, Bian M, Shan J, et al. Preoperative tumor biopsy results in more detected sentinel nodes than intraoperative biopsy in breast cancer patients. World J Surg Oncol. 2020;18:178. https://doi.org/10.1186/s12957-020-01942-4.CrossRefPubMedPubMedCentral

12.

Pesapane F, Suter MB, Rotili A, Penco S, Nigro O, Cremonesi M, et al. Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation? Med Oncol. 2020;37:29. https://doi.org/10.1007/s12032-020-01353-1.CrossRefPubMed

13.

Mason CA, Kossatz S, Carter LM, Pirovano G, Brand C, Guru N, et al. An (89)Zr-HDL PET Tracer Monitors response to a CSF1R inhibitor. J Nucl Med. 2020;61:433–6. https://doi.org/10.2967/jnumed.119.230466.CrossRefPubMedPubMedCentral

14.

Shu CJ, Guo S, Kim YJ, Shelly SM, Nijagal A, Ray P, et al. Visualization of a primary anti-tumor immune response by positron emission tomography. Proc Natl Acad Sci U S A. 2005;102:17412–7. https://doi.org/10.1073/pnas.0508698102.CrossRefPubMedPubMedCentral

15.

Pisaneschi F, Gammon ST, Paolillo V, Qureshy SA, Piwnica-Worms D. Imaging of innate immunity activation in vivo with a redox-tuned PET reporter. Nat Biotechnol. 2022;40:965–73. https://doi.org/10.1038/s41587-021-01169-y.CrossRefPubMedPubMedCentral

16.

Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang SY, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018;564:439–43. https://doi.org/10.1038/s41586-018-0705-y.CrossRefPubMed

17.

Fang J, Zhang J, Meng L, Li H, Xia D, Wang Y, et al. ¹⁸F-Labeled Amidobenzimidazole Analogue for visualizing STING expression in Tumor. Mol Pharm. 2024;21:1942–51. https://doi.org/10.1021/acs.molpharmaceut.3c01201.CrossRefPubMed

18.

Fang J, Feng L, Meng L, Wang X, Liu H, Huang L, et al. A novel ¹⁸F-labeled agonist for PET imaging of stimulator of interferon gene expression in tumor-bearing mice. Eur J Nucl Med Mol Imaging. 2022;50:27–37. https://doi.org/10.1007/s00259-022-05959-7.CrossRefPubMed

19.

Pan BS, Perera SA, Piesvaux JA, Presland JP, Schroeder GK, Cumming JN, et al. An orally available non-nucleotide STING agonist with antitumor activity. Science. 2020;369:eaba6098. https://doi.org/10.1126/science.aba6098.CrossRefPubMed

20.

Xu D, Yang F, Chen J, Zhu T, Wang F, Xiao Y, et al. Novel STING-targeted PET radiotracer for alert and therapeutic evaluation of acute lung injury. Acta Pharm Sin B. 2023;13:2124–37. https://doi.org/10.1016/j.apsb.2022.12.017.CrossRefPubMed

21.

Xu D, Lu X, Yang F, Jiang Z, Yang S, Bi L, et al. STING-targeted PET tracer for early assessment of tumor immunogenicity in colorectal cancer after chemotherapy. Eur J Nucl Med Mol Imaging. 2023;51:641–55. https://doi.org/10.1007/s00259-023-06485-w.CrossRefPubMed

22.

Fang J, Wang X, Meng L, Zhang J, Zhuang R, Li Y, et al. Preclinical evaluation of ¹³¹I/¹⁸F-Labeled covalent small-molecule inhibitors for STING Status Imaging. ACS Pharmacol Translational Sci. 2024;7:1783–94. https://doi.org/10.1021/acsptsci.3c00398.CrossRef

23.

Liu H, Sun Y, Li J, Chen Y, Liu J, Fang J, et al. Development of ¹⁸F-Labeled Acridone Analogue for Tumor Imaging via Stimulator of Interferon genes targeting. Mol Pharm. 2023;20:3529–38. https://doi.org/10.1021/acs.molpharmaceut.3c00137.CrossRefPubMed

24.

Lee W, Bobba KN, Kim JY, Park H, Bhise A, Kim W, et al. A short PEG linker alters the in vivo pharmacokinetics of trastuzumab to yield high-contrast immuno-PET images. J Mater Chem B. 2021;9:2993–7. https://doi.org/10.1039/d0tb02911d.CrossRefPubMed

25.

Wu X, You L, Zhang D, Gao M, Li Z, Xu D, et al. Synthesis and preliminary evaluation of a ¹⁸F-labeled ethisterone derivative [¹⁸F]EAEF for progesterone receptor targeting. Chem Biol Drug Des. 2017;89:559–65. https://doi.org/10.1111/cbdd.12878.CrossRefPubMed

26.

Gao F, Peng C, Zhuang R, Guo Z, Liu H, Huang L, et al. ¹⁸F-Labeled ethisterone derivative for progesterone receptor targeted PET imaging of breast cancer. Nucl Med Biol. 2019;72–3. https://doi.org/10.1016/j.nucmedbio.2019.07.001.

27.

Hou S, Lan XJ, Li W, Yan XL, Chang JJ, Yang XH, et al. Design, synthesis and biological evaluation of acridone analogues as novel STING receptor agonists. Bioorg Chem. 2020;95:103556. https://doi.org/10.1016/j.bioorg.2019.103556.CrossRefPubMed

28.

Bu Y, Liu F, Jia QA, Yu SN. Decreased expression of TMEM173 predicts poor prognosis in patients with Hepatocellular Carcinoma. PLoS ONE. 2016;11:e0165681. https://doi.org/10.1371/journal.pone.0165681.CrossRefPubMedPubMedCentral

29.

Raaby Gammelgaard K, Sandfeld-Paulsen B, Godsk SH, Demuth C, Meldgaard P, Sorensen BS, et al. cGAS-STING pathway expression as a prognostic tool in NSCLC. Transl Lung Cancer Res. 2021;10:340–54. https://doi.org/10.21037/tlcr-20-524.CrossRefPubMedPubMedCentral

30.

Le TM, Lee HR, Abt ER, Rashid K, Creech AL, Liang K, et al. ¹⁸F-FDG PET visualizes systemic STING Agonist-Induced lymphocyte activation in preclinical models. J Nucl Med. 2023;64:117–23. https://doi.org/10.2967/jnumed.122.264121.CrossRefPubMedPubMedCentral

31.

Liang K, Abt ER, Le TM, Cho A, Dann AM, Cui J, et al. STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [¹⁸F]FLT PET imaging. Proc Natl Acad Sci U S A. 2021;118:e2105390118. https://doi.org/10.1073/pnas.2105390118.CrossRefPubMedPubMedCentral

Titel: Development of STING probes and visualization of STING in multiple tumor types
verfasst von: Huanhuan Liu
Jia Liu
Yingxi Chen
Hongzhang Yang
Jianyang Fang
Xinying Zeng
Jingru Zhang
Shilan Peng
Yuanyuan Liang
Rongqiang Zhuang
Gang Liu
Xianzhong Zhang
Zhide Guo
Publikationsdatum: 18.09.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2025
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-024-06919-z

PET/CT with [68Ga]Ga-TEoS-DAZA for localization of a traumatic biliary leak

Image of the Month

The impact of integrating PRIMARY score or SUVmax with MRI-based risk models for the detection of clinically significant prostate cancer

Original Article

Fluorescence detection of pituitary neuroendocrine tumour during endoscopic transsphenoidal surgery using bevacizumab-800CW: a non-randomised, non-blinded, single centre feasibility and dose finding trial [DEPARTURE trial]

Open Access
Original Article

Updated practice guideline for dual-energy X-ray absorptiometry (DXA)

Open Access
Review Article

Characterization of a gonadal vein Capillary Hemangioma by [68Ga]FAPI-46 and [18 F]FDG PET and immunohistochemistry: a potential pitfall of FAPI PET signal

Image of the Month

Ferdinando Calabria, Orazio Schillaci (editors). Radiopharmaceuticals. A guide to PET/CT and PET/MRI, 3rd edition. Springer Nature Switzerland AG 2024. ISBN 978-3-031-54195-7

Book Review

Springer Medizin

Development of STING probes and visualization of STING in multiple tumor types

Abstract

Purpose

Methods

Results

Conclusion

Graphical Abstract

Weitere Artikel der Ausgabe 2/2025

PET/CT with [68Ga]Ga-TEoS-DAZA for localization of a traumatic biliary leak

The impact of integrating PRIMARY score or SUVmax with MRI-based risk models for the detection of clinically significant prostate cancer

Fluorescence detection of pituitary neuroendocrine tumour during endoscopic transsphenoidal surgery using bevacizumab-800CW: a non-randomised, non-blinded, single centre feasibility and dose finding trial [DEPARTURE trial]

Updated practice guideline for dual-energy X-ray absorptiometry (DXA)

Characterization of a gonadal vein Capillary Hemangioma by [68Ga]FAPI-46 and [18 F]FDG PET and immunohistochemistry: a potential pitfall of FAPI PET signal

Ferdinando Calabria, Orazio Schillaci (editors). Radiopharmaceuticals. A guide to PET/CT and PET/MRI, 3rd edition. Springer Nature Switzerland AG 2024. ISBN 978-3-031-54195-7

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Graphical Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

PET/CT with [68Ga]Ga-TEoS-DAZA for localization of a traumatic biliary leak

The impact of integrating PRIMARY score or SUVmax with MRI-based risk models for the detection of clinically significant prostate cancer

Fluorescence detection of pituitary neuroendocrine tumour during endoscopic transsphenoidal surgery using bevacizumab-800CW: a non-randomised, non-blinded, single centre feasibility and dose finding trial [DEPARTURE trial]

Updated practice guideline for dual-energy X-ray absorptiometry (DXA)

Characterization of a gonadal vein Capillary Hemangioma by [68Ga]FAPI-46 and [18 F]FDG PET and immunohistochemistry: a potential pitfall of FAPI PET signal

Ferdinando Calabria, Orazio Schillaci (editors). Radiopharmaceuticals. A guide to PET/CT and PET/MRI, 3rd edition. Springer Nature Switzerland AG 2024. ISBN 978-3-031-54195-7